Replaces Prod. #: ALX-430-002
SIN-1 is a metabolite of molsidomine which decomposes spontaneously in solution in the presence of oxygen, releasing NO and superoxide anion under physiological conditions. Since NO and superoxide react to form peroxynitrite, SIN-1 may actually produce peroxynitrite under physiological conditions. It is a potent vasodilator and inhibitor of platelet aggregation and produces significant protective effects in myocardial ischemia-reperfusion. The effects of SIN-1 are markedly attenuated by nitroglycerin-induced tolerance. Inhibits cysteine proteases.
Product Details
| Alternative Name: | SIN-1, Linsidomine |
| |
| Formula: | C6H10N4O2 . HCl |
| |
| MW: | 206.6 |
| |
| CAS: | 33876-97-0 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | White to off-white solid. |
| |
| MeltingPoint: | 186-187°C |
| |
| Solubility: | Soluble in water (25mg/ml), 100% ethanol or DMSO (>5mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Use freshly prepared solutions. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
(2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone: A. Laghezza, et al.; Pharmaceuticals (Basel)
14, 85 (2021),
Abstract;
Tissue-specific contributions of Tmem79 to atopic dermatitis and mast cell-mediated histaminergic itch: J.J. Emrick, et al.; PNAS
115, 12091 (2018),
Application(s): Neuronal cell culture,
Abstract;
Full Text
Modification of HSP proteins and Ca2+ are responsible for the NO-derived peroxynitrite mediated neurological damage in PC12 cell: J. Wen, et al.; Int. J. Clin. Exp. Pathol.
8, 4492 (2015),
Abstract;
Full Text
EPR detection of cellular and mitochondrial superoxide using cyclic hydroxylamines: S.I. Dikalov, et al.; Free Rad. Res.
45, 417 (2011),
Abstract;
Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase: N. Kuzkaya et al.; Biochem. Pharmacol.
70, 343 (2005),
Abstract;
New glycosidase activated nitric oxide donors: glycose and 3-morphorlinosydnonimine conjugates: T.B. Cai et al.; J. Org. Chem.
70, 3518 (2005),
Abstract;
In vitro cytotoxicity of glyco-S-nitrosothiols. a novel class of nitric oxide donors: H. Babich & H.L. Zuckerbaun; Toxicol. In Vitro
15, 181 (2001),
Abstract;
An activity in rat tissues that modifies nitrotyrosine-containing proteins: Y. Kamisaki et al.; PNAS
95, 11584 (1998),
Abstract;
A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds: S.A. Lipton et al.; Nature
364, 626 (1993),
Abstract;
Neuronal growth cone collapse and inhibition of protein fatty acylation by nitric oxide: D.T. Hess et al.; Nature
366, 562 (1993),
Abstract;
Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation: P.F. Mery et al.; J. Biol. Chem.
268, 26286 (1993),
Abstract;
Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion: M.R. Siegfried et al.; J. Pharmacol. Exp. Ther.
260, 668 (1992),
Abstract;
Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex: S.Z. Lei et al.; Neuron
8, 1087 (1992),
Abstract;
Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide: N. Hogg et al.; Biochem. J.
281 , 419 (1992),
Abstract;
Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade: P.J. Henry et al.; J. Pharmacol. Exp. Ther.
248, 762 (1989),
Abstract;
Molsidomine: alternative approaches to treat myocardial ischemia: R.-E. Nitz & V.B. Fiedler; Pharmacotherapy
7, 28 (1987),
Abstract;
Regulation of cyclic GMP formation by soluble guanylate cyclase: stimulation by NO-containing compounds: E. Bohme et al.; Adv. Cyclic Nucleotide Protein Phosphorylation Res.
17, 259 (1984),
Abstract;
Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites: M. Nishikawa et al.; J. Phar.macol. Exp. Ther.
220, 183 (1982),
Abstract;
